Calidi Biotherapeutics (CLDI) said Thursday it has priced its offering of about 4.44 million shares at $1.69 apiece, targeting gross proceeds of $7.5 million.
The company intends to use the net proceeds for working capital, general corporate purposes, and pre-clinical and clinical trials.
Shares slumped 36% intraday.
Bragg Gaming (BRAG) reported higher Q3 revenue and concluded a strategic review, saying that ongoing execution of its strategy best option to maximize shareholder value. The company also said it is "currently tracking to the lower end of guidance" for 2024.
Shares sank 27% as intraday trading volume jumped to over 461,000 versus a daily average of about 32,000.
Chardan downgraded Allurion Technologies (ALUR) to neutral from buy following Q3 results released Wednesday.
Shares of Allurion sank 25% as intraday trading volume climbed to more than 684,000 from a daily average of roughly 186,000.
Price: 2.18, Change: -1.20, Percent Change: -35.50
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。